Showing results (101-110 of 118) with videos related to
Sort By:
Pageof 12
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell deathJoanne M Hildebrand, Maria C Tanzer, Isabelle S Lucet, et al.Science Advances|March 5, 2025
Differential regulation of BAX and BAK apoptotic activity revealed by small moleculesKaiming Li, Yu Q Yap, Donia M Moujalled, et al.Journal of Medicinal Chemistry|July 11, 2003
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirusKeith G Watson, Renee N Brown, Rachel Cameron, et al.Blood|October 11, 2022
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemiaDonia M Moujalled, Fiona C Brown, Chong Chyn Chua, et al.Journal of Medicinal Chemistry|June 18, 2013
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XLBrad E Sleebs, Wilhemus J A Kersten, Sanji Kulasegaram, et al.ACS Chemical Biology|September 9, 2020
Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the PathwayCatia L Pierotti, Maria C Tanzer, Annette V Jacobsen, et al.Leukemia|September 15, 2018
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemiaDonia M Moujalled, Giovanna Pomilio, Corina Ghiurau, et al.Nature Communications|June 21, 2020
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosisAndre L Samson, Ying Zhang, Niall D Geoghegan, et al.Blood Advances|June 23, 2020
Cotargeting BCL-2 and MCL-1 in high-risk B-ALLDonia M Moujalled, Diane T Hanna, Soroor Hediyeh-Zadeh, et al.Frontiers in Chemistry|May 2, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro InhibitorsDale J Calleja, Nathan Kuchel, Bernadine G C Lu, et al.Pageof 12